Proven Lyme disease treatment offered by top lab

In clinical practice, it has long been reported that a subset of Lyme disease patients experience a range of symptoms such as exhaustion, cognitive problems, and musculoskeletal pain, which may last for a prolonged period of time. Such symptoms, which may vary from mild to extreme, have been documented in prospective and population-based studies in endemic regions of Lyme disease throughout the literature.

After Lyme disease was first described in the late 1970s in the United States, but before the pathogenic bacteria were known, it was noticed that untreated Lyme arthritis patients have often reported recurrent symptoms such as headache, exhaustion, myalgia, and hyperesthesia. In some of the earliest cases series of treated patients it was first reported that these symptoms could persist after antibiotic treatment

The etiology of these symptoms is unclear, but several disease-causing mechanisms, including microbial persistence, host immune dysregulation by inflammatory or secondary autoimmune pathways, or impaired neural networks, have been hypothesized as in central sensitization. Assessment and classification of chronic Lyme disease symptoms is complicated by possible discrete, frequent exposures to B. Burgdorferi, as well as potential for conflicting symptom patterns of co-morbid diseases.

Checking antibody for B. The burgdorferi is an insulting measure after diagnosis, and there are currently no other FDA-approved tests. As such, diagnosis poses a daunting problem for physicians, while patient experience is one marked by confusion and sometimes invalidation of the illness.

There are currently no prescription therapies approved by the FDA, and the efficacy and effectiveness of off-label and/or alternative therapies have not been well tested and are not decided upon within the medical community. Post-treatment Lyme disease represents a small, defined, mechanistic-neutral subset of this larger, more heterogeneous category of patients, and is a useful concept as an initial subgroup of study in research settings.

Labs like Igenex Lab for Lyme test provide the existing literature on Lyme disease diagnosis, etiology, risk factors and treatment of patients with recurrent symptoms. The importance and relevance of current patient subgroups will be addressed, as will future research goals, including the need to establish biomarkers for diseases, elucidate disease biological mechanisms, and drive improvements in therapeutic options.

Clinically, Lyme disease presents dermatological and/or viral-like signs and symptoms such as persistent fever, sweats, chills, fatigue, tiredness, and achiness during the acute period, which can lead to neurological, cardiac, and/or joint involvement in later stages of infection as the bacteria propagate hematogenously.

IGeneX Lyme Lab test has been at the forefront of researching and improving medical procedures for Lyme disease for over 25 years. These BCA assays yield either a positive or negative result for exposure to Borreliae, according to the press release provided by IGengeX.

Along with these objective signs, persistent and recurring symptoms such as exhaustion, sleep disturbance, arthralgia, myalgia, and headache are often frequently present during later stages of untreated Lyme disease, and can account for the majority of patient symptom experience (9). For example, patients with sporadic late Lyme arthritis outbreaks continued to experience these symptoms during the intervening intervals.

Occasionally, signs remain the primary or simple manifestations of untreated Lyme disease infection without physical examination, laboratory, or other so-called "objective" findings. The specification for B of direct tests such as history, polymerase chain reaction (PCR) or antigen detection. Burgdorferi is extremely confined to assist clinicians in diagnosis, and B. In non-research settings the burgdorferi can not be cultivated.

Testing for each Borreliosis disorder is important because the TBRF Borreliae community can also cause Lyme-like symptoms, and the treatments may be different as per IGengeX Lyme disease treatment. The BCA Assays for Lyme and TBRF are designed to detect antibodies in human serum for various species and strains of Lyme Borreliae and TBRF Borreliae, respectively.